{"nctId":"NCT00004978","briefTitle":"An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy","startDateStruct":{"date":"2000-03"},"conditions":["HIV Infections"],"count":4150,"armGroups":[{"label":"rIL-2","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant interleukin-2 (rIL-2)"]},{"label":"No rIL-2","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Recombinant interleukin-2 (rIL-2)","otherNames":["Proleukin","IL-2","Aldesleukin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV positive\n* Have a CD4 cell count of 300 cells/mm3 or more within 45 days of study entry\n* Are on combination anti-HIV therapy or are beginning anti-HIV therapy at the time of study entry\n* Are at least 18 years old\n\nExclusion Criteria:\n\n* Have received IL-2 before\n* Have cancer requiring chemotherapy\n* Have evidence of active clinical disease within the past year for any AIDS-defining illness or certain other conditions such as herpes zoster or Chagas disease. (This study has been changed. Previously, patients were ineligible if they had a history of any AIDS-defining illness or certain other conditions.)\n* Have used certain medications, such as corticosteroids or drugs affecting the immune system, in the 45 days before study entry\n* Have a nervous system disorder requiring antiseizure medication\n* Have an autoimmune or inflammatory disease such as inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), psoriasis, optic neuritis, or any autoimmune/inflammatory diseases with potentially life-threatening complications\n* Are pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"New or Recurrent HIV Disease Progression Event Including Death","description":"Participants who die or experience at least one: any CDC Category C 1993 AIDS-defining events or one of the following: invasive aspergillosis, bartonellosis, Chagas disease, Herpes zoster, visceral Leishmaniasis, Hodgkin's lymphoma, non-Hodgkin's lymphoma (all cell types), microsporidiosis, nocardiosis, disseminated Penicillium marneffii, extrapulmonary Pneumocystis carinii, and Rhodococcus equi disease","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]}]},{"type":"SECONDARY","title":"New or Recurrent Serious HIV Disease Progression Event Including Death","description":"Patients with at least one: progressive multifocal leukoencephalopathy, lymphoma, visceral Kaposi's sarcoma, AIDS dementia complex, toxoplasmosis, histoplasmosis, cryptococcosis, Mycobacterium avium complex, wasting syndrome, and cytomegalovirus disease.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died From Any Cause","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With a New Disease Progression Event or Death","description":"Includes first new episode of: CDC Category C 1993 AIDS-defining events plus invasive aspergillosis, bartonellosis, Chagas disease, Herpes zoster, visceral Leishmaniasis, Hodgkin's lymphoma, non-Hodgkin's lymphoma (all cell types), microsporidiosis, nocardiosis, disseminated Penicillium marneffii, extrapulmonary Pneumocystis carinii, and Rhodococcus equi disease","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute CD4 Cell Counts Averaged Throughout Followup","description":"Average of all available CD4+ cell counts measured at follow-up visits","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"715.4","spread":"273.1"},{"groupId":"OG001","value":"556.3","spread":"193.0"}]}]}]},{"type":"SECONDARY","title":"Plasma HIV RNA Levels","description":"log10 HIV-RNA averaged throughout follow-up","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"0.65"},{"groupId":"OG001","value":"2.17","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Changes in Anti-retroviral Treatment (ART)","description":"Number of participants who changed ART at least once during the study period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1760","spread":null},{"groupId":"OG001","value":"1751","spread":null}]}]}]},{"type":"SECONDARY","title":"Grade 4 Signs and Symptoms","description":"Participants with at least one grade 4 sign or symptom (except those limited to a laboratory measurement), other than AIDS-defining conditions. Events were graded according to a standardized toxicity table. Events not specifically contained in the toxicity table were considered Grade 4 if they resulted in extreme limitation in activity or required significant medical intervention/therapy, hospitalization or hospice care. Grade 4 events by type are given under the adverse events section.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"466","spread":null},{"groupId":"OG001","value":"383","spread":null}]}]}]},{"type":"SECONDARY","title":"Pattern of Use of Prophylaxis for Opportunistic Infections","description":"Number of participants using pneumocystis pneumonia (PCP) prophylaxis at the last attended followup visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatic, Metabolic, and Cardiac Conditions","description":"Number of participants experiencing a \"serious non-AIDS\" event defined as first serious cardiovascular, renal, or hepatic event, or non-AIDS malignancy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":466,"n":2071},"commonTop":["Myocardial infarction","Acute myocardial infarction","Pyrexia","Diarrhoea","Coronary artery disease"]}}}